{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:08:39Z","timestamp":1791544119460,"version":"4.3.4"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:p>\n                    In their 2018 article, Lezcano et al [\n                    <jats:italic toggle=\"yes\">AJSP<\/jats:italic>\n                    2018(11):1456] show that diffuse tumor cell nuclear reactivity for Preferentially expressed Antigen in Melanoma (PRAME) is a feature of melanoma and that benign and atypical melanocytic tumors are PRAME negative or show only focal positivity for PRAME. We report our observations of PRAME staining in 253 melanocytic tumors. Tumors were classified by hematoxylin and eosin sections. The nuclear PRAME staining of neoplastic melanocytes in each case was categorized as absent, focally present, or diffusely present. The results were compared with those of Lezcano et al 105 of 134 (78%) melanocytic nevi were completely PRAME negative. Of the 29 PRAME-positive benign lesions, 28 exhibited focal but not diffuse positivity, including atypical (n = 11) and dysplastic nevi (n = 11). One of 11 Spitz nevi showed diffuse positivity (9%). Thirty-nine of 51 (76%) invasive melanomas, 41 of 50 (82%) melanoma in situ, and 15 of 18 (83%) metastatic melanomas were diffusely PRAME positive. Excluding desmoplastic melanomas, 39 of 49 (80%) primary melanomas were diffusely PRAME positive. Our findings of PRAME staining in melanocytic neoplasia are in general agreement with those of Lezcano et al. Diffuse PRAME reactivity in neoplastic melanocytes is a feature of malignancy and was only otherwise seen in 1 Spitz nevus. Caution is advised in interpretation of PRAME reactivity in melanocytic tumors of uncertain classification because melanoma arising in association with nevus and some atypical melanocytic tumors may show focal or incomplete PRAME staining. Routine histopathological findings, clinical information, PRAME staining, and judicious application of molecular studies are steps leading to accurate classification of melanocytic neoplasia.\n                  <\/jats:p>","DOI":"10.1097\/dad.0000000000001885","type":"journal-article","created":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T14:00:56Z","timestamp":1621000856000},"page":"794-800","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":42,"title":["Preferentially Expressed Antigen in Melanoma Immunostaining in a Series of Melanocytic Neoplasms"],"prefix":"10.1097","volume":"43","author":[{"given":"Paul B.","family":"Googe","sequence":"first","affiliation":[{"name":"Dermatology, and"},{"name":"Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendall L.","family":"Flanigan","sequence":"additional","affiliation":[{"name":"AU\/UGA Medical Partnership, Medical College of Georgia, Athens, GA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayson R.","family":"Miedema","sequence":"additional","affiliation":[{"name":"Dermatology, and"},{"name":"Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,5,11]]},"reference":[{"key":"R1-20250616","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0002-9440(10)63536-5","article-title":"Classifying melanocytic tumors based on DNA copy number changes","volume":"163","author":"Bastian","year":"2003","journal-title":"Am J Pathol."},{"key":"R2-20250616","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1097\/PAS.0b013e3181a1ef36","article-title":"Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma","volume":"33","author":"Gerami","year":"2009","journal-title":"Am J Surg Pathol."},{"key":"R3-20250616","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1158\/1055-9965.EPI-16-0958","article-title":"Diagnostic distinction of malignant melanoma and benign nevi by a gene expression signature and correlation to clinical outcomes","volume":"26","author":"Ko","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"R4-20250616","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13000-015-0431-9","article-title":"A p16-Ki-67-HMB45 immunohistochemistry scoring system as an ancillary diagnostic tool in the diagnosis of melanoma","volume":"10","author":"Uguen","year":"2015","journal-title":"Diagn Pathol."},{"key":"R5-20250616","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1074-7613(00)80426-4","article-title":"Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor","volume":"6","author":"Ikeda","year":"1997","journal-title":"Immunity"},{"key":"R6-20250616","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1097\/PAS.0000000000001134","article-title":"PRAME expression in melanocytic tumors","volume":"42","author":"Lezcano","year":"2018","journal-title":"Am J Surg Pathol."},{"key":"R7-20250616","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/PAS.0000000000001492","article-title":"Comparison of immunohistochemistry for PRAME with cytogenetic test results in the evaluation of challenging melanocytic tumors","volume":"44","author":"Lezcano","year":"2020","journal-title":"Am J Surg Pathol."},{"key":"R8-20250616","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/PAS.0000000000001393","article-title":"Immunohistochemistry for PRAME in the distinction of nodal nevi from metastatic melanoma","volume":"44","author":"Lezcano","year":"2020","journal-title":"Am J Surg Pathol."},{"key":"R9-20250616","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/cup.13818","article-title":"PRAME expression in melanocytic proliferations with intermediate histopathologic or spitzoid features","volume":"47","author":"Raghavan","year":"2020","journal-title":"J Cutan Pathol."},{"key":"R10-20250616","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/cup.13876","article-title":"PRAME expression in 155 cases of metastatic melanoma","volume":"48","author":"Gradecki","year":"2020","journal-title":"J Cutan Pathol."},{"key":"R11-20250616","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1158\/1078-0432.CCR-11-2524","article-title":"PRAME-induced inhibition of retinoic acid receptor signaling-mediated differentiation - a possible target for ATRA response in AML without t(15;17)","volume":"19","author":"Bullinger","year":"2013","journal-title":"Clin Cancer Res."},{"key":"R12-20250616","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.leukres.2008.10.010","article-title":"Array CGH analysis of chronic lymphocytic leukemia reveals frequent cryptic monoallelic and biallelic deletions of chromosome 22q11 that include the PRAME gene","volume":"33","author":"Gunn","year":"2009","journal-title":"Leuk Res."},{"key":"R13-20250616","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/cjp2.16","article-title":"Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma","volume":"1","author":"Iura","year":"2015","journal-title":"J Pathol Clin Res."},{"key":"R14-20250616","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.humpath.2016.12.006","article-title":"Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1","volume":"61","author":"Iura","year":"2017","journal-title":"Hum Pathol."},{"key":"R15-20250616","author":"Neumann"},{"key":"R16-20250616","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1158\/1078-0432.CCR-03-0813","article-title":"The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome","volume":"10","author":"Oberthuer","year":"2004","journal-title":"Clin Cancer Res."},{"key":"R17-20250616","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1016\/j.jtho.2016.08.120","article-title":"Safety and immunogenicity of the prame cancer immunotherapeutic in patients with resected non-small cell lung cancer: a phase I dose escalation study","volume":"11","author":"Pujol","year":"2016","journal-title":"J Thorac Oncol."},{"key":"R18-20250616","doi-asserted-by":"crossref","first-page":"45352","DOI":"10.18632\/oncotarget.9977","article-title":"PRAME expression and promoter hypomethylation in epithelial ovarian cancer","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"R19-20250616","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1158\/1078-0432.CCR-15-2071","article-title":"PRAME as an independent biomarker for metastasis in uveal melanoma","volume":"22","author":"Field","year":"2016","journal-title":"Clin Cancer Res."},{"key":"R20-20250616","doi-asserted-by":"crossref","first-page":"59209","DOI":"10.18632\/oncotarget.10962","article-title":"Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in class 1 and class 2 uveal melanomas","volume":"7","author":"Field","year":"2016","journal-title":"Oncotarget"},{"key":"R21-20250616","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/cncr.30385","article-title":"An independent validation of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi","volume":"123","author":"Clarke","year":"2017","journal-title":"Cancer"},{"key":"R22-20250616","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1001\/jamadermatol.2017.0473","article-title":"Utility of a noninvasive 2-gene molecular assay for cutaneous melanoma and effect on the decision to biopsy","volume":"153","author":"Ferris","year":"2017","journal-title":"JAMA Dermatol."},{"key":"R23-20250616","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2217\/bmm.12.65","article-title":"The cancer testis antigen PRAME as a biomarker for solid tumor cancer management","volume":"6","author":"Goodison","year":"2012","journal-title":"Biomark Med."},{"key":"R24-20250616","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/cup.12475","article-title":"Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma","volume":"42","author":"Clarke","year":"2015","journal-title":"J Cutan Pathol."},{"key":"R25-20250616","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1016\/j.jid.2015.11.035","article-title":"Discrimination of dysplastic nevi from common melanocytic nevi by cellular and molecular criteria","volume":"136","author":"Mitsui","year":"2016","journal-title":"J Invest Dermatol."},{"key":"R26-20250616","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/esmoopen-2016-000068","article-title":"Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase i dose escalation study","volume":"1","author":"Gutzmer","year":"2016","journal-title":"ESMO Open"},{"key":"R28-20250616","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1097\/PAS.0000000000000189","article-title":"Fluorescence in situ hybridization as an ancillary tool in the diagnosis of ambiguous melanocytic neoplasms","volume":"38","author":"North","year":"2014","journal-title":"Am J Surg Pathol."}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000001885","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T15:02:42Z","timestamp":1750086162000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000001885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,11]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000001885","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.740115064.793590667","asserted-by":"object"}]},"ISSN":["0193-1091"],"issn-type":[{"value":"0193-1091","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,11]]}}}